CD274 and neoplasm: Therefore, ROS level in tumoral and lymphatic cells might be a potential indicator of the responsiveness to PD-1/PD-L1 blockade therapy, especially considering that the expression of immune checkpoints has been accepted as a tumor-intrinsic sign of the vulnerability of tumors to ICB therapy (Zappasodi et al., 2018).